Rhabdomyosarcoma Recurrent

When rhabdomyosarcoma returns after treatment, it presents one of the most challenging situations in childhood cancer care, with nearly one-third of patients with localized disease and over two-thirds with metastatic disease experiencing recurrence, typically within three years of initial diagnosis.

Table of contents

• What is recurrent rhabdomyosarcoma
• How often does rhabdomyosarcoma come back
• When does recurrence typically occur
• Factors affecting the likelihood of relapse and outcomes
• Prognosis after relapse
• Approach to treatment for recurrent disease
• Clinical trials and emerging treatments

What is recurrent rhabdomyosarcoma

Recurrent rhabdomyosarcoma means that the cancer comes back after it has been treated^[1]. Rhabdomyosarcoma is a type of soft tissue sarcoma, which is cancer that develops in the body’s soft tissues such as muscles. It most commonly affects children and adolescents^[2].

The cancer can return in the same location where it first appeared, or it may come back in a different part of the body^[3]. When cancer spreads to a new location, doctors carefully evaluate where the disease has returned and what treatments were used initially to determine the best approach moving forward.

How often does rhabdomyosarcoma come back

Relapsed rhabdomyosarcoma represents a significant therapeutic challenge. An estimated 25 to 30 percent of patients diagnosed with localized rhabdomyosarcoma still experience relapses, despite advances in treatment over recent decades^[1]. The situation is more concerning for patients who initially have metastatic disease—meaning cancer that has already spread to other parts of the body at diagnosis. For these patients, relapse rates approach 70 percent^[1].

Nearly all recurrences of rhabdomyosarcoma occur within three years of the initial diagnosis^[8]. This timeline is important for understanding when patients need especially close monitoring and follow-up care.

When does recurrence typically occur

Following primary treatment for rhabdomyosarcoma, disease recurrence generally happens within three years^[1]. The time between initial treatment and relapse is an important factor that doctors consider when making decisions about further care. Patients who experience relapse earlier after treatment may face different challenges than those whose cancer returns later.

Factors affecting the likelihood of relapse and outcomes

Multiple factors influence both the likelihood that rhabdomyosarcoma will come back and how patients fare after relapse. Clinical features present at the original diagnosis play an important role. These include where in the body the tumor first appeared (the primary site), how invasive the tumor was, its size, the stage (how far the cancer had spread), and the type of rhabdomyosarcoma based on how cells look under a microscope (histology)^[1].

Aspects of the initial treatment also affect post-relapse outcomes. The extent of surgical removal of the tumor, whether radiation therapy was used, and which chemotherapy drugs were given all influence what happens if the cancer returns^[1].

Features of the relapse itself matter as well. How much time passed between the end of initial treatment and when the cancer came back is significant. The extent of disease when it returns—whether it is limited to one area or has spread to multiple locations—also impacts the outlook^[1].

Prognosis after relapse

Following relapse, there is currently no standard treatment that works for all patients with recurrent rhabdomyosarcoma^[1]. The outlook varies considerably depending on the specific characteristics of each patient’s disease.

Some patients have features that suggest a more favorable prognosis. These include children with botryoid rhabdomyosarcoma (a subtype that develops in hollow organs) or stage 1 or group I embryonal rhabdomyosarcoma who have not previously received treatment with a chemotherapy drug called cyclophosphamide. These patients have the highest chance of achieving long-term cure when treated with a combination of multiple chemotherapy drugs at the time of relapse^[1].

Unfortunately, patients who do not meet these favorable criteria represent the majority of those with recurrent disease. These patients have poor outcomes when treated with standard combination chemotherapy regimens^[1]. If the disease recurs, especially in cases where it has spread widely, the survival rate drops significantly, and mortality is high^[7].

Approach to treatment for recurrent disease

When rhabdomyosarcoma returns, several important principles should guide the approach to care. Doctors recommend obtaining a tissue biopsy (removal of a small sample of tissue) to confirm the diagnosis of recurrence. They assess the post-relapse prognosis based on various factors and determine whether additional local control measures—such as surgery or radiation—are possible. Discussion of the patient’s goals is also an essential part of planning care^[1].

Treatment for recurrent rhabdomyosarcoma may be based on several considerations: where in the body the cancer has come back, what treatments the child has already received, and the child’s age and overall health^[3].

Treatment may involve surgery, chemotherapy, radiation therapy, or a combination of these approaches^[3]. Surgery may be used to remove a tumor that comes back in the same location as the original tumor. Sometimes surgery can remove cancer that has recurred in the lungs, lymph nodes, or other locations^[3].

Chemotherapy is often used when rhabdomyosarcoma returns in a different part of the body than the original tumor. The specific drugs given depend on what the child has already received during initial treatment^[3].

Radiation therapy may be an option if it was not already given to the area where the cancer has returned^[3].

Some specialized centers offer cutting-edge treatment options for relapsed disease. One example is a procedure that combines surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) to treat rhabdomyosarcoma that has relapsed in the abdomen and pelvis. In this approach, surgeons remove all visible tumors and apply heated chemotherapy directly into the patient’s abdomen. Unlike chemotherapy given through the bloodstream (systemic chemotherapy), HIPEC delivers treatment directly to the affected area^[7].

Clinical trials and emerging treatments

For patients with recurrent rhabdomyosarcoma who do not have favorable prognostic features, strong consideration should be given to enrollment in a clinical trial^[1]. Clinical trials are research studies that look at new ways to prevent, find, and treat cancer^[3].

Children with cancer may be treated in a clinical trial, which offers access to newer treatments that are being studied to determine if they work better than current standard approaches^[3]. Because outcomes with standard treatments remain poor for most patients with relapsed rhabdomyosarcoma, participation in research studies provides both potential benefit to the individual patient and contributes to advancing knowledge that may help future patients.